Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma

Bookmark and Share
Published: 4 Dec 2018
Views: 812
Rating:
Save
Prof Thierry Facon - Hôpital Claude Huriez, Lille, France

Prof Thierry Facon speaks to ecancer at ASH 2018 about results from the DARA trial.

He explains that the trial has found that daratumumab increases PFS in patients with transplant-ineligible multiple myeloma.

Prof Facon added that the trial is important as it has the potential to establish daratumumab as the new standard of care for patients with transplant-ineligible newly diagnosed multiple myeloma.

Read more about this work here

Watch his press conference here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.